Jade Biosciences, Inc.
JBIO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$958.41M
Close$
$2.80
82.4% downside
Current Fair Value
82.4% downsideOvervalued by 82.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $958.41 Million |
|---|---|
| Enterprise Value | $851.79 Million |
| Earnings per Share | $-4.06 |
| Beta | 1.45 |
| Outstanding Shares | 61,050,775 |
Return
| Return on Equity | -42.94% |
|---|---|
| Return on Assets | -40.01% |
| Return on Invested Capital | -42.44% |
Valuation & Multiples
| P/E Ratio | -5.48 |
|---|---|
| PEG | -7.45 |
| Price to Sales | - |
| Price to Book Ratio | 2.27 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.56 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 12, 2026
EPS Estimate
-$0.73
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 193.41% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.94%▼ 120.44% |
|---|---|
| Total Invested | $50.93M▼ 96.86% |
| Investors Holding | 42▼ 116.00% |
About Jade Biosciences, Inc.
50 employees
CEO: Tom Frohlich
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) ...